ArticleJournal of the American Heart Association2026
Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A predictive model for adverse events in left heart failure patients based on cardiopulmonary ultrasound parameters and clinical predictors.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary arterial hypertension (PAH) is a progressive disease driven by pulmonary vascular remodeling, largely due to the abnormal proliferation and phenotypic switching of pulmonary artery smooth muscle cells.
methodsLevels of topoisomerase II α were evaluated in the lungs from patients with idiopathic PAH, 2 rodent PAH models (SU5416 combined with hypoxia and monocrotaline-induced), and in pulmonary artery smooth muscle cells stimulated with platelet-derived growth factor BB (PDGF-BB). The therapeutic potential of amonafide, a topoisomerase II inhibitor, was also evaluated in these models. Integrated transcriptomic and metabolomic analyses were used to identify amonafide-regulated pathways. The role of neurotensin receptor 1 (NTSR1) was further investigated through overexpression and knockdown experiments in pulmonary artery smooth muscle cells.
resultsTopoisomerase II α was significantly upregulated in the lungs of patients with idiopathic PAH, SU5416 combined with hypoxia-, and monocrotaline-induced rodent PAH models, and PDGF-BB-stimulated pulmonary artery smooth muscle cells. This upregulation was associated with increased DNA damage and apoptosis resistance. Amonafide treatment markedly improved hemodynamics, attenuated right ventricular hypertrophy, and suppressed pulmonary vascular remodeling in both animal models. In vitro, amonafide inhibited PDGF-BB-induced pulmonary artery smooth muscle cell proliferation, migration, apoptosis resistance, and DNA damage. Mechanistically, amonafide downregulated NTSR1 expression and inhibited the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway. Crucially, NTSR1 overexpression abolished the beneficial effects of amonafide, whereas NTSR1 knockdown enhanced them.
conclusionsOur findings unveil the pivotal role of amonafide in PAH pathogenesis and suggest that targeting topoisomerase II α and NTSR1 may be a promising therapeutic approach for treating PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.